Market Intelligence, Clinical Progress, and High-Purity Reagents for Mitochondrial Quality Control Targeting.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for OMA1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | OMA1 Full-Length / Catalytic Domain / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Conformation). |
View OMA1 Products |
| Gene Delivery | OMA1 Lentivirus Particles Full-length ORF with mitochondrial targeting sequence for stable cell line construction in HEK293 or neuronal models. |
View OMA1 Products |
| Validator | OMA1 siRNA Set (3 unique sequences) For knockdown verification and specificity controls in functional assays. |
View OMA1 Products |
| Reference Control | Anti-OMA1 Recombinant Antibody Research-grade binding control for assay development. |
View OMA1 Products |
| Related Target: OPA1 | OPA1 (Optic Atrophy 1) Primary substrate for OMA1 proteolytic activity; essential for mitochondrial fusion assays. |
View OPA1 Products |
| Related Target: YME1L | YME1L (YME1 Like 1 ATPase) Paralogous mitochondrial protease; critical for selectivity counter-screening. |
View YME1L Products |
| Related Target: PARL | PARL (Presenilin Associated Rhomboid Like) Mitochondrial rhomboid protease; orthogonal off-target liability control. |
View PARL Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Membrane Topology Fidelity (Mitochondrial Inner Membrane Insertion) | Full-length OMA1 Lentivirus for Stable Cell Lines; preserves native N-terminal TM domains and catalytic zinc-binding site orientation. |
| Cross-species Preclinical Evaluation (Cyno/Rat/Mouse) | Human/Mouse/Rat/Cyno ortholog proteins available with >95% purity; species-specific activity validation enabled. |
| Subfamily Selectivity (vs. m-AAA Proteases & Rhomboids) | Homolog Panel: YME1L, AFG3L2, PARL recombinant proteins strictly verified by Mass Spec for counter-screening. |
| Functional Knockdown Controls | Validated siRNA Set included; sequence-verified for specific OMA1 mRNA degradation without off-target mitochondrial stress. |
| OPA1 Cleavage Activity Measurement | Matched OPA1 Substrate Protein available; HEK293 expressed with native glycosylation for Biacore/SPR and FRET-based assays. |
| Lack of Catalytic Controls | WT & Catalytic Dead Mutant (Active Site Disrupted) recombinant proteins included as enzymatic references. |
Live OMA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for OMA1-targeted therapeutics is accelerating as mitochondrial dysfunction gains recognition as a central node in neurodegeneration and cardiovascular disease. Currently positioned predominantly in preclinical and early discovery phases, OMA1 inhibitors are being evaluated for their ability to prevent OPA1 cleavage and maintain mitochondrial fusion during cellular stress. As first-generation small molecules advance toward IND-enabling studies, the field is pivoting toward highly selective allosteric inhibitors that spare the paralogous YME1L protease to avoid compensatory pathway toxicity. The next wave of R&D is expected to advance lead compounds toward IND-enabling studies, with combination strategies alongside mitochondrial uncouplers and autophagy inducers gaining traction.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (Allosteric) | Mitobridge (Astellas), Academic Consortia | Parkinson's Disease, ALS | Selectivity Assay: Need purified YME1L/PARL for counter-screening; OMA1 mutants for binding site mapping. |
| Small Molecule Inhibitors (Active Site) | Emerging Biotechs | Heart Failure, Ischemia-Reperfusion Injury | Cell-based Functional Assay: Lentivirus-stable lines expressing OMA1-OPA1 FRET reporters for high-throughput screening. |
| Gene Silencing (siRNA/mRNA) | Specialized Delivery Platforms | Acute Kidney Injury | Knockdown Validation: High-specificity siRNA sets with matched negative controls. |
| PROTAC / Degrader | Academic Consortia | Solid Tumors | Intracellular Target Engagement (Need native-folding stable cell lines) |
Key Mutations and Genetic Variants
OMA1 mutations are associated with disease and drug resistance. Key variants include:
- rs34466938: A variant in dbSNP, evidence from UniProt Q96E52 VAR_034958.
- rs75220198: Found in a patient with amyotrophic lateral sclerosis; evidence from UniProt Q96E52 VAR_065755.
- rs17117720: A variant in dbSNP, evidence from UniProt Q96E52 VAR_034959.
These mutations are critical for understanding OMA1 function in disease and for developing selective inhibitors.